Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | PPARG | P37231 | 2/20 | 0.41 |
| ▸ | PPARD | Q03181 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | DRD4 | P21917 | 1/20 | 0.40 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dimethylformamide SCHEMBL6715442 | 0.95 | KDM4E (0.43) | KDM4EPPARGPPARDHTTDRD2 | |
| SCHEMBL3864617 | 0.89 | PPARG (0.45) | KDM4EPPARGMEN1KMT2A | |
| SCHEMBL3862382 | 0.84 | KDM4E (0.47) | KDM4EPPARGPPARDHTTDRD2 | |
| SCHEMBL3877174 | 0.84 | KDM4E (0.49) | KDM4EPPARGPPARDFFAR1 | |
| Dimethylformamide SCHEMBL6715439 | 0.80 | KDM4E (0.45) | KDM4EPPARGPPARDFFAR1MEN1 | |
| SCHEMBL6950641 | 0.78 | TSHR (0.46) | NPC1RAB9AKMT2A | |
| SCHEMBL3874788 | 0.77 | F2 (0.36) | — | |
| SCHEMBL3866649 | 0.76 | KDM4E (0.49) | KDM4EPPARGPPARDFFAR1RAB9A | |
| Hydrochloric Acid SCHEMBL3863877 | 0.75 | KDM4E (0.48) | KDM4EPPARGPPARDFFAR1RAB9A | |
| Hydrochloric Acid SCHEMBL3862950 | 0.75 | ACHE (0.53) | KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090149444-A1 | Benzylamine analogues | BTG INTERNATIONAL LIMITED (GB) | 2009-06-11 | — | — | US | disclosed |
| US-7514475-B2 | Benzylamine analogues | BTG INTERNATIONAL LIMITED (GB) | 2009-04-07 | — | — | US | disclosed |
| US-7504437-B2 | Benzylamine analogues | BTG INTERNATIONAL LIMITED (GB) | 2009-03-17 | — | — | US | disclosed |
| US-7504393-B2 | Benzylamine analogues | BTG INTERNATIONAL LIMITED (GB) | 2009-03-17 | — | — | US | disclosed |
| US-20080255095-A1 | Benzylamine analogues | BTG INTERNATIONAL LIMITED (GB) | 2008-10-16 | — | — | US | disclosed |
| EP-1362844-B1 | BENZYLAMINE ANALOGUE | BTG INT LTD (GB) | 2007-12-05 | — | — | EP | disclosed |
| US-20070037795-A1 | 2-methyl-1-[2-(4-nitrophenoxy)-ethyl]-1,2,3,4-tetrahydroisoquinolin-6-yl dimethylcarbamate; Acetylcholinesterase inhibitors; selective serotonin reuptake inhibitory; Alzheimer's disease, depression, Huntington's chorea, Pick's disease, tardive dyskinesia, compulsive disorders or panic disorders | BTG INTERNATIONAL LIMITED (GB) | 2007-02-15 | — | — | US | disclosed |
| US-20070037793-A1 | 2-methyl-1-[2-(4-nitrophenoxy)-ethyl]-1,2,3,4-tetrahydroisoquinolin-6-yl dimethylcarbamate; Acetylcholinesterase inhibitors; selective serotonin reuptake inhibitory; Alzheimer's disease, depression, Huntington's chorea, Pick's disease, tardive dyskinesia, compulsive disorders or panic disorders | BTG INTERNATIONAL LIMITED (GB) | 2007-02-15 | — | — | US | disclosed |
| US-20040067981-A1 | Acetylcholinesterase inhibitor; Alzheimer's diseases, Hubtington disease, antidepressants | SANKYO COMPANY, LIMITED (JP) | 2004-04-08 | — | — | US | disclosed |
| EP-1362844-A1 | BENZYLAMINE ANALOGUE | Sankyo Company, Limited (JP) | 2003-11-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037793-A1 | 2-methyl-1-[2-(4-nitrophenoxy)-ethyl]-1,2,3,4-tetrahydroisoquinolin-6-yl dimethylcarbamate; Acetylcholinesterase inhibitors; selective serotonin reuptake inhibitory; Alzheimer's disease, depression, Huntington's chorea, Pick's disease, tardive dyskinesia, compulsive disorders or panic disorders | CHRNA4, SLC6A4, DRD4 | KDM4E 1420/4885PPARG 2932/4885PPARD 3170/4885 |
| US-20070037795-A1 | 2-methyl-1-[2-(4-nitrophenoxy)-ethyl]-1,2,3,4-tetrahydroisoquinolin-6-yl dimethylcarbamate; Acetylcholinesterase inhibitors; selective serotonin reuptake inhibitory; Alzheimer's disease, depression, Huntington's chorea, Pick's disease, tardive dyskinesia, compulsive disorders or panic disorders | SLC6A4, SLC6A3, HTR4 | KDM4E 1874/4885PPARG 2631/4885PPARD 2900/4885 |
| US-20040067981-A1 | Acetylcholinesterase inhibitor; Alzheimer's diseases, Hubtington disease, antidepressants | ACHE, BACE1, CHRNA6 | KDM4E 1990/4885PPARG 3650/4885PPARD 3803/4885 |
| US-20090149444-A1 | Benzylamine analogues | HTR4, DRD4, SLC6A4 | KDM4E 2718/4885PPARG 3434/4885PPARD 3422/4885 |
| US-20080255095-A1 | Benzylamine analogues | NR4A3, NAT1, HRH4 | KDM4E 1803/4885PPARG 2638/4885PPARD 1657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.